The DCT OS Report: More than 95% of biopharma executives say we're not going back to a site-based-only development model. Learn more

News

New Science 37<sup>®</sup> Report: Nearly 100% of Biopharma Executives Expect Clinical Trial Decentralization to Increase Yet Lack Internal Capabilities to Operationalize
New Science 37® Report: Nearly 100% of Biopharma Executives Expect Clinical Trial Decentralization to Increase Yet Lack Internal Capabilities to Operationalize

Science 37, pioneer of the Decentralized Clinical Trial Operating System™ (DCT OS), today unveiled the DCT OS Report, which highlights the growing trend of decentralization in research and th...

CONTINUE
Science 37<sup>®</sup> to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future
Science 37® to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future

LOS ANGELES and NEW YORK, May 7, 2021 – Science 37, Inc. (“Science 37”), developer of the Decentralized Clinical Trial Operating System™, an...

CONTINUE
PPD and Science 37<sup>®</sup> Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development
PPD and Science 37® Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development

PPD, Inc., a leading global contract research organization (CRO), and Science 37, developer of the Decentralized Clinical Trial Operating System™ (DCT...

CONTINUE
Syneos Health<sup>®</sup> Partners with Science 37<sup>®</sup> to Transform Clinical Trials – Increasing Speed and Diversity
Syneos Health® Partners with Science 37® to Transform Clinical Trials – Increasing Speed and Diversity

Syneos Health® and Science 37 today announced a strategic partnership to enable enhanced decentralized clinical trial delivery. Together, Science 37 and Syneos Health will offer...

CONTINUE
Science 37<sup>®</sup> and Xperiome<sup>™</sup> Partner to Increase the Efficiency and Speed of Rare Disease Studies for Patients and Providers
Science 37® and Xperiome™ Partner to Increase the Efficiency and Speed of Rare Disease Studies for Patients and Providers

Science 37 announced today a partnership with Xperiome, a global rare disease healthtech company. The partnership further strengthens Science 37's capabilities to bring research directly to pat...

CONTINUE
Science 37<sup>®</sup> and Medgate Partner to Further Globalize Decentralized Clinical Trials
Science 37® and Medgate Partner to Further Globalize Decentralized Clinical Trials

Science 37 announced today a strategic partnership with Medgate, a leading international digital health and telemedicine company and operator of Europe’s largest telemedicine center run by ph...

CONTINUE
Science 37<sup>®</sup> and Signant Health</b> Partner to Expand Access to CNS Research with Decentralized Clinical Trials
Science 37® and Signant Health Partner to Expand Access to CNS Research with Decentralized Clinical Trials

Science 37 and Signant Health have announced a partnership to strengthen capabilities for decentralized or virtual CNS clinical research. By bringing research to patients at home, the partnership w...

CONTINUE
Science 37<sup>®</sup> Supports DCRI's First Direct-to-Family Study for Pediatric Lupus
Science 37® Supports DCRI's First Direct-to-Family Study for Pediatric Lupus

Science 37 is excited to be part of the first-of-its-kind direct-to-family study with the Duke Clinical Research Institute (DCRI) for decentralized research in pediatric lupus. The iPERSONAL (Indiv...

CONTINUE
Science 37<sup>®</sup> Integrates Electronic Health Records into Its Decentralized Clinical Trial Technology Platform
Science 37® Integrates Electronic Health Records into Its Decentralized Clinical Trial Technology Platform

Patients using Science 37's technology platform can now connect their health record directly, in real time, eliminating paper documentation and streamlining information sharing LOS ANGELES, Sep...

CONTINUE
John Hubbard, Ph.D., Joins Science 37<sup>®</sup> Board of Directors
John Hubbard, Ph.D., Joins Science 37® Board of Directors

LOS ANGELES, September 2, 2020 -  Science 37, the industry leader in decentralized clinical trials, today announced the appointment of industry veteran John Hubbard, Ph.D., FCP to its Board of...

CONTINUE
ERT and Science 37<sup>®</sup> Partner to Deliver High-Quality Data during Virtual Trials
ERT and Science 37® Partner to Deliver High-Quality Data during Virtual Trials

Technology partnership enables trial sponsors to improve imaging, respiratory, and cardiac safety data quality while reducing patient burden and risk.   PHILADELPHIA & LOS ANGELES, August ...

CONTINUE
Science 37<sup>®</sup> Raises $40 Million to Extend Its Leadership in the Decentralized Clinical Trial Market
Science 37® Raises $40 Million to Extend Its Leadership in the Decentralized Clinical Trial Market

In a significantly oversubscribed offering, Science 37 attracted capital to support its rapid growth, expand its technology platform, and accelerate global expansion. LOS ANGELES, August 20, 2020 -...

CONTINUE
Page 1 of 3
123